Atle Fund Management AB Grows Position in Soleno Therapeutics, Inc. $SLNO

Atle Fund Management AB boosted its position in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) by 48.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 60,156 shares of the company’s stock after buying an additional 19,624 shares during the period. Soleno Therapeutics accounts for approximately 1.6% of Atle Fund Management AB’s portfolio, making the stock its 24th biggest holding. Atle Fund Management AB’s holdings in Soleno Therapeutics were worth $4,067,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of SLNO. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Soleno Therapeutics by 1.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,360 shares of the company’s stock valued at $1,242,000 after purchasing an additional 189 shares during the last quarter. Raymond James Financial Inc. acquired a new position in Soleno Therapeutics in the second quarter valued at $25,000. New York State Common Retirement Fund raised its holdings in shares of Soleno Therapeutics by 2.4% in the third quarter. New York State Common Retirement Fund now owns 15,600 shares of the company’s stock valued at $1,055,000 after buying an additional 360 shares during the last quarter. Nisa Investment Advisors LLC boosted its stake in shares of Soleno Therapeutics by 287.8% during the second quarter. Nisa Investment Advisors LLC now owns 539 shares of the company’s stock worth $45,000 after buying an additional 400 shares during the period. Finally, Osaic Holdings Inc. increased its position in Soleno Therapeutics by 97.7% in the 2nd quarter. Osaic Holdings Inc. now owns 856 shares of the company’s stock valued at $72,000 after acquiring an additional 423 shares during the period. 97.42% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

SLNO has been the subject of a number of recent research reports. Wolfe Research set a $60.00 price objective on Soleno Therapeutics in a research report on Monday, January 12th. Robert W. Baird set a $107.00 price target on Soleno Therapeutics in a research note on Tuesday, January 13th. Wall Street Zen upgraded shares of Soleno Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. The Goldman Sachs Group set a $125.00 price objective on shares of Soleno Therapeutics and gave the company a “buy” rating in a research note on Tuesday, October 7th. Finally, HC Wainwright restated a “buy” rating and issued a $120.00 target price (up previously from $110.00) on shares of Soleno Therapeutics in a research note on Tuesday, January 20th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $110.62.

Soleno Therapeutics Stock Performance

NASDAQ:SLNO opened at $38.56 on Friday. The company has a quick ratio of 15.88, a current ratio of 16.08 and a debt-to-equity ratio of 0.10. Soleno Therapeutics, Inc. has a fifty-two week low of $37.95 and a fifty-two week high of $90.32. The firm’s fifty day simple moving average is $46.58 and its 200-day simple moving average is $59.63. The stock has a market cap of $2.07 billion, a PE ratio of -20.96 and a beta of -3.12.

Soleno Therapeutics (NASDAQ:SLNO) last released its quarterly earnings data on Tuesday, November 4th. The company reported $0.47 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.39. The company had revenue of $66.02 million for the quarter, compared to analysts’ expectations of $47.46 million. Analysts expect that Soleno Therapeutics, Inc. will post -3.72 earnings per share for the current fiscal year.

Soleno Therapeutics Profile

Soleno Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small?molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.